Belite plots pipeline progress vs. cash

 

Belite Bio Phase III Stargardt trial cuts lesion growth 36% vs placebo as cash build funds NDA and launch

• Phase III Stargardt trial met primary endpoint with 36% lesion growth reduction versus placebo.
• Rolling NDA submission for Tinlarebant on track for Q2 2026, CSR finalizing imminently.
• Company targeting Q1 2027 U.S. launch with 25–30-person commercial field organization.
• Cash and investments rose to $772.6 million, supporting R&D and commercialization plans.
• Company completed $402 million ADS offering alongside its Q4 and full-year 2025 update.
• Next three years R&D spend estimated at ~$150 million; commercialization $200–$250 million.

https://finviz.com/quote.ashx?t=BLTE&p=d